Literature DB >> 18634076

Anti-histones antibodies in systemic lupus erythematosus: prevalence and frequency in neuropsychiatric lupus.

Xiao-Yun Sun1, Jinxia Shi, Lei Han, Yin Su, Zhan-Guo Li.   

Abstract

To investigate the specificity, sensitivity, and concomitant presence of antibodies against histones (H), histone H1 (H1), and histone H3 (H3) in patients with systemic lupus erythematosus (SLE) and analyze their association with SLE. Serum IgG anti-histones antibodies were detected by enzyme-linked immunosorbent assay in 144 SLE patients consisting of 24 neuropsychiatric lupus (NPSLE), 65 lupus nephritis (LN), and 55 SLE, 100 other rheumatic diseases patients, as well as 40 healthy controls. Clinical and biological parameters of the patients were also evaluated. Anti-H, anti-H1, and anti-H3 antibodies yielded a sensitivity of approximately 33% and a specificity of more than 93% for SLE, which was comparable to that found for anti-double-stranded DNA (anti-dsDNa) antibodies. More significantly, anti-histone antibody is found in approximately 50% of patients with NPSLE compared with LN. Moreover, the titers of anti-histones antibodies of NPSLE patients were significantly higher than that of patients with SLE and LN. The sequential analysis revealed a close correlation of anti-H and anti-H1 antibodies with SLE disease activity. There was an approximate 30% positive rate of anti-histones antibodies in 144 SLE patients lacking anti-nucleosome, anti-mDNA, anti-Sm, and anti-dsDNA antibodies. Antibodies to histones H1 and H3 are markers with high specificity of 93.6-96.4% for SLE. The anti-histone antibody markers are prevalent in approximately 50% of NPSLE. Furthermore, there was a strong correlation with SLE disease activity index and levels of antibodies to histones and H1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18634076      PMCID: PMC6649061          DOI: 10.1002/jcla.20248

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  36 in total

Review 1.  Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology.

Authors:  E M Tan
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

2.  The autoimmune response to chromatin antigens in systemic lupus erythematosus: autoantibodies against histone H1 are a highly specific marker for SLE associated with increased disease activity.

Authors:  G Schett; J Smole; C Zimmermann; H Hiesberger; E Hoefler; S Fournel; S Muller; R L Rubin; G Steiner
Journal:  Lupus       Date:  2002       Impact factor: 2.911

Review 3.  The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes.

Authors: 
Journal:  Arthritis Rheum       Date:  1999-04

4.  Correlation between clinical features of systemic lupus erythematosus and levels of antihistone antibodies of the IgG, IgA, and IgM isotypes.

Authors:  N R Gompertz; D A Isenberg; B M Turner
Journal:  Ann Rheum Dis       Date:  1990-07       Impact factor: 19.103

5.  Prevalence and antigen specificity of anti-histone antibodies in patients with polymyositis/dermatomyositis.

Authors:  M Kubo; H Ihn; N Yazawa; S Sato; K Kikuchi; K Tamaki
Journal:  J Invest Dermatol       Date:  1999-05       Impact factor: 8.551

6.  Longitudinal analysis of antibodies to histones, Sm-D peptides and ubiquitin in the serum of patients with systemic lupus erythematosus, rheumatoid arthritis and tuberculosis.

Authors:  S Muller; S Barakat; R Watts; P Joubaud; D Isenberg
Journal:  Clin Exp Rheumatol       Date:  1990 Sep-Oct       Impact factor: 4.473

7.  Antihistone antibodies in systemic lupus erythematosus: assay dependency and effects of ubiquitination and serum DNA.

Authors:  T Suzuki; R W Burlingame; C A Casiano; M L Boey; R L Rubin
Journal:  J Rheumatol       Date:  1994-06       Impact factor: 4.666

8.  The prevalence of antibodies to histones induced by procainamide in old people, in cancer patients, and in rheumatoid-like disease.

Authors:  A Klajman; B Kafri; T Shohat; I Drucker; T Moalem; A Jaretzky
Journal:  Clin Immunol Immunopathol       Date:  1983-04

9.  Antibodies to histones in systemic lupus erythematosus.

Authors:  E Fishbein; D Alarcon-Segovia; J M Vega
Journal:  Clin Exp Immunol       Date:  1979-04       Impact factor: 4.330

10.  Antihistone and anti-double-stranded deoxyribonucleic acid antibodies are associated with renal disease in systemic lupus erythematosus.

Authors:  Josefina Cortés-Hernández; Josep Ordi-Ros; Moisés Labrador; Segundo Buján; Eva Balada; Alfons Segarra; Miquel Vilardell-Tarrés
Journal:  Am J Med       Date:  2004-02-01       Impact factor: 4.965

View more
  16 in total

1.  Deimination of linker histones links neutrophil extracellular trap release with autoantibodies in systemic autoimmunity.

Authors:  Nishant Dwivedi; Indira Neeli; Nicolas Schall; Haibao Wan; Dominic M Desiderio; Elena Csernok; Paul R Thompson; Hayet Dali; Jean-Paul Briand; Sylviane Muller; Marko Radic
Journal:  FASEB J       Date:  2014-03-26       Impact factor: 5.191

Review 2.  Antigen-specific immunotherapies in rheumatic diseases.

Authors:  Judit Pozsgay; Zoltán Szekanecz; Gabriella Sármay
Journal:  Nat Rev Rheumatol       Date:  2017-07-13       Impact factor: 20.543

Review 3.  Chance, genetics, and the heterogeneity of disease and pathogenesis in systemic lupus erythematosus.

Authors:  Tony N Marion; Arnold E Postlethwaite
Journal:  Semin Immunopathol       Date:  2014-08-08       Impact factor: 9.623

4.  Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice.

Authors:  Samanta C Funes; Mariana Ríos; Felipe Gómez-Santander; Ayleen Fernández-Fierro; María J Altamirano-Lagos; Daniela Rivera-Perez; Raul Pulgar-Sepúlveda; Evelyn L Jara; Diego Rebolledo-Zelada; Alejandra Villarroel; Juan C Roa; Juan P Mackern-Oberti; Alexis M Kalergis
Journal:  Immunology       Date:  2019-10-07       Impact factor: 7.397

Review 5.  Breaking immunological tolerance in systemic lupus erythematosus.

Authors:  Elmar Pieterse; Johan van der Vlag
Journal:  Front Immunol       Date:  2014-04-09       Impact factor: 7.561

Review 6.  Clearance Deficiency and Cell Death Pathways: A Model for the Pathogenesis of SLE.

Authors:  Aparna Mahajan; Martin Herrmann; Luis E Muñoz
Journal:  Front Immunol       Date:  2016-02-08       Impact factor: 7.561

7.  Autoantibodies against Modified Histone Peptides in SLE Patients Are Associated with Disease Activity and Lupus Nephritis.

Authors:  Jürgen Dieker; Jo H Berden; Marinka Bakker; Jean-Paul Briand; Sylviane Muller; Reinhard Voll; Christopher Sjöwall; Martin Herrmann; Luuk B Hilbrands; Johan van der Vlag
Journal:  PLoS One       Date:  2016-10-25       Impact factor: 3.240

Review 8.  Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians?

Authors:  Kevin Didier; Loïs Bolko; Delphine Giusti; Segolene Toquet; Ailsa Robbins; Frank Antonicelli; Amelie Servettaz
Journal:  Front Immunol       Date:  2018-03-26       Impact factor: 7.561

9.  Novel candidate drugs in anti-tumor necrosis factor refractory Crohn's diseases: in silico study for drug repositioning.

Authors:  Min Seob Kwak; Hun Hee Lee; Jae Myung Cha; Hyun Phil Shin; Jung Won Jeon; Jin Young Yoon
Journal:  Sci Rep       Date:  2020-07-01       Impact factor: 4.379

10.  The Predictive Value of Autoantibody Spectrum on Organ Damage in Patients With Systemic Lupus Erythematosus.

Authors:  Fang Yuan; Fenghua Wei; Haiting Huang; Yi Xue; Pengwei Guo; Yanwu You
Journal:  Arch Rheumatol       Date:  2018-08-16       Impact factor: 1.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.